Quinoxalines, also known as benzopyrazines, are heterocyclic compounds containing a ring complex consisting of a benzene ring and a pyrazine ring. It has isomerism with other naphthalene compounds such as quinazoline, phthalazine, cinnamine, etc. Fusion N-heterocyclic compounds are widely used as valuable entities for the expansion of important pharmacological agents and are considered to be an advantageous scaffold material. Among the numerous fused N-heterocyclic compounds, cinnoline, quinoxaline and quinazoline are important pharmacological agents. In medicinal chemistry, these N-heterocyclic compounds have a wide range of biological properties and can be used as synthetic intermediates, potential drug candidates and chemical probes.
Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.
Sunobinop is an investigational, novel and potential first-in-class oral compound discovered by Imbrium Therapeutics and that is currently in clinical development. Sunobinop is designed to bind to and activate the nociceptin/orphanin-FQ peptide receptor (NOP), a protein that is widely expressed in the central and peripheral nervous system and involved in a range of biological functions, including bladder function.
As of Feb 2024, it is under clinical investigation for the treatment of insomnia/alcohol use disorder, interstitial cystitis, and overactive bladder syndrome. It was previously also under investigation for the treatment of fibromyalgia.
Buscar 
+86 21 5895 0110 
